Webinar: Perspectives on the Future of Pegfilgrastim Biosimilars

September 27, 2017 6:45 AM


Cinfa Biotech is organizing a webinar on October, 11th, titled “Perspectives on the Future of Pegfilgrastim Biosimilars”.

Biosimilars were one of the key topics of the recent European Society for Medical Oncology Congress (ESMO) in Madrid 2017. At the congress, Cinfa Biotech presented data from the clinical development program of B12019, a biosimilar candidate for pegfilgrastim (reference product Neulasta) to treat chemotherapy-induced neutropenia.

Cinfa Biotech now invites you to join a webinar discussion on the significance of pegfilgrastim biosimilars in oncology.

Prof. Dr. Pere Gascón, Director Laboratory of Molecular & Translational Oncology-CELLEX, Barcelona, Spain will give an overview of the current developments in pegfilgrastim therapy and perspectives of bio­similars in this field. Dr. Rüdiger Jankowsky, Managing Director at Cinfa Biotech and Dr. Karsten Roth, Director Clinical Operations at Cinfa Biotech, will provide scientific insights into the development program of B12019 and will discuss data in the context of the current biosimilars landscape.

The WebEx will be organized on October 11th, at 4:30 – 5:15 pm CEST and can be accessed through the following web address: https://mc-events.webex.com/mc-events

Would you like to post an event on Biosimilar News?

1 Comment

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!